<DOC>
	<DOC>NCT00709917</DOC>
	<brief_summary>This study is conducted in Europe. The aim of this observational study is to investigate the switch from metformin alone to metformin combined with repaglinide in type 2 diabetic patients not achieving adequate glycaemic control on maximal dose of metformin given alone and to analyse different epidemiological parameters.</brief_summary>
	<brief_title>Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetic patients with inadequate glycaemic control when received metformin alone on maximal dose Signed informed consent Treatment in accordance with the summary of product characterisation Any contraindication to metformin or repaglinide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>